The stock is up 140% this year already.In this video, I will talk about recent updates regarding Hims & Hers Health (HIMS -1.01%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Feb. 14, 2025. The video was published on Feb. 14, 2025. ...

Hims & Hers Health, Inc.’s (HIMS) investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 156.9% in the past three months, outperforming the industry’s 28.3% gain. In the same time frame, the stock outperformed the sector and S&P 500’s 0.3% rise and 3.6% growth, respectively.Two major developments of HIMS in recent months include the announcement of its promising third-quarter 2024 results and the launch of ...

The stock has sprinted past $50 per share, after trading at $3 less than two years ago.Shares of direct-to-consumer telehealth platform Hims & Hers Health (HIMS 2.18%) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a blistering 490% over the past year alone. Those who got in early may have already made life-changing money on this stock.Its momentum is no fluke. The company has continually touted robust growth, driven by a subscriber base that ...

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $60.30, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a loss of 0.37%, and the technology-centric Nasdaq increased by 0.41%.Shares of the company have appreciated by 111.81% over the course of the past month, outperforming the Medical sector's gain of 3.39% and the S&P 500's gain of 4.88%.Analysts and investors alike will be keepin ...

SYDNEY, AUSTRALIA - JANUARY 13: Ozempic is medicine for adults with type 2 diabetes . Wegovy is ... [+] prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia (Photo by Steve Christo - Corbis/Corbis via Getty Images)Corbis via Getty ImagesThe stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has surged an impressive 43% over the past week. A major driver of this growth was the company's widel ...

Company Overview - Hims & Hers Health, Inc. (HIMS) shares increased by 27.7% in the last trading session, closing at $59.18, with a notable trading volume compared to typical sessions [1] - The stock has experienced a significant 66.3% gain over the past four weeks, reaching a new all-time high following a successful Super Bowl advertisement [1] Earnings Expectations - The company is projected to report quarterly earnings of $0.12 per share, reflecting a year-over-year increase of 1100% [2] - Expected revenues for the upcoming report are $471.42 million, which is a 91.2% increase from the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Hims & Hers Health has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Context - Hims & Hers Health operates within the Zacks Medical Info Systems industry, which includes other companies like Nyxoah SA (NYXH) [3] - Nyxoah's consensus EPS estimate for its upcoming report is -$0.48, representing a 17.1% decline from the previous year, and it also holds a Zacks Rank of 3 (Hold) [4]

Big pharma tried to stop Hims & Hers' Super Bowl ad.Hims & Hers (HIMS 1.51%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the company's disruptive potential is real.*Stock prices used were end-of-day prices of Feb. 11, 2025. The video was published on Feb. 12, 2025. ...

Much of this owes to the 350% gains in the stock in the past year alone, which followed subscriber andMy articles are written with a mind to owning a stock for years, not trying to predict price movements in a few months. I don't do target prices; I do valuations.I first entered investing in 2020 as an individual value investor, keen to understand the fundamentals of businesses and buy their shares at attractive prices. From May 2022 to May 2023, I worked as an investment advisory representative at Fidelity ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NVO -2.90%), famously the company behind Wegovy, and Viking Therapeutics (VKTX -7.34%), which is far along in its development of an advanced GLP-1-based obesity treatment. The gainer was Hims & Hers Healthcare (HIMS 5.22%).On the day, the latter company's share price rose by over 5%, while Novo Nordisk's slid by almost 3%, and Viking took a more than 7% tumble.A ...

Core Insights - Hims & Hers Health has transformed into a healthcare platform focusing on personalized and affordable solutions through a telehealth model, indicating strong growth potential in the healthcare sector [1] Company Overview - The company is positioned to become a household name due to its innovative approach and financial performance [1] Industry Context - The emphasis on telehealth solutions reflects a broader trend in the healthcare industry towards digital and remote care, which is increasingly being adopted by consumers [1]